Literature DB >> 17110166

Feature-similarity protein classifier as a ligand engineering tool.

Sridhar Maddipati1, Ariel Fernández.   

Abstract

Kinases have been often targeted in drug therapy aimed at blocking signaling pathways. However, the conservation of protein structure across homologs often leads to uncontrolled cross-reactivity. On the other hand, sticky packing defects in proteins are typically not conserved across homologs, making them ligand-anchoring sites potentially important to enhance selectivity. Thus, we introduce a hierarchical clustering of PDB-reported kinases according to packing differences. This kinome partitioning is highly correlated with proximity relations arising from the pharmacological profiling of kinases. A variable packing sensitivity is observed for individual drugs, with highly promiscuous ligands being the most insensitive to packing differences. Our classifier enables a strategy to design selective inhibitors.

Mesh:

Substances:

Year:  2006        PMID: 17110166      PMCID: PMC1945244          DOI: 10.1016/j.bioeng.2006.09.004

Source DB:  PubMed          Journal:  Biomol Eng        ISSN: 1389-0344


  17 in total

1.  Clinical use of tyrosine kinase inhibitors: therapy for chronic myelogenous leukemia and other cancers.

Authors:  N J Donato; M Talpaz
Journal:  Clin Cancer Res       Date:  2000-08       Impact factor: 12.531

Review 2.  Targeting protein kinases in cancer therapy.

Authors:  Doriano Fabbro; Carlos García-Echeverría
Journal:  Curr Opin Drug Discov Devel       Date:  2002-09

Review 3.  Protein kinases--the major drug targets of the twenty-first century?

Authors:  Philip Cohen
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

Review 4.  Protein kinase inhibitors: insights into drug design from structure.

Authors:  Martin E M Noble; Jane A Endicott; Louise N Johnson
Journal:  Science       Date:  2004-03-19       Impact factor: 47.728

Review 5.  Kinomics-structural biology and chemogenomics of kinase inhibitors and targets.

Authors:  Michal Vieth; Richard E Higgs; Daniel H Robertson; Michael Shapiro; Ellen A Gragg; Horst Hemmerle
Journal:  Biochim Biophys Acta       Date:  2004-03-11

6.  Incomplete protein packing as a selectivity filter in drug design.

Authors:  Ariel Fernández
Journal:  Structure       Date:  2005-12       Impact factor: 5.006

Review 7.  Issues and progress with protein kinase inhibitors for cancer treatment.

Authors:  Janet Dancey; Edward A Sausville
Journal:  Nat Rev Drug Discov       Date:  2003-04       Impact factor: 84.694

8.  The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.

Authors:  Samir Attoub; Christine Rivat; Sylvie Rodrigues; Saskia Van Bocxlaer; Monique Bedin; Erik Bruyneel; Christophe Louvet; Michel Kornprobst; Thierry André; Marc Mareel; Jan Mester; Christian Gespach
Journal:  Cancer Res       Date:  2002-09-01       Impact factor: 12.701

9.  Inhibitor design by wrapping packing defects in HIV-1 proteins.

Authors:  Ariel Fernández; Kristina Rogale; Ridgway Scott; Harold A Scheraga
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-02       Impact factor: 11.205

10.  Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase.

Authors:  Clifford D Mol; Douglas R Dougan; Thomas R Schneider; Robert J Skene; Michelle L Kraus; Daniel N Scheibe; Gyorgy P Snell; Hua Zou; Bi-Ching Sang; Keith P Wilson
Journal:  J Biol Chem       Date:  2004-04-29       Impact factor: 5.157

View more
  3 in total

1.  A mechanism for propagated SOD1 misfolding from frustration analysis of a G85R mutant protein assembly.

Authors:  Eamonn F Healy
Journal:  Biochem Biophys Res Commun       Date:  2016-08-31       Impact factor: 3.575

2.  A model for non-obligate oligomer formation in protein aggregration.

Authors:  Eamonn F Healy
Journal:  Biochem Biophys Res Commun       Date:  2015-08-15       Impact factor: 3.575

3.  A prion-like mechanism for the propagated misfolding of SOD1 from in silico modeling of solvated near-native conformers.

Authors:  Eamonn F Healy
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.